 |
|
|
|
lamivudine - abacavir [Epzicom] |
|
Detailed Prescribing Information |
|
October 2005 |
|
Epzicom A combination of lamivudine + abacavir Approved 8-2-2004 |
|
| Forms Available | 300 mg lamivudine / 600 mg abacavir in tablets |
| Dosing | 1 tablet once a day |
| Renal dosing: not recommended for Ccr < 50 cc/min | |
| Hepatic dosing: not recommended for hepatic failure | |
| Food dependence | Epzicom may be taken with or without food. |
| Adverse Effects | Same as lamivudine plus abacavir (see above or click on the drug name) |
| Interactions | Same as lamivudine plus abacavir (see above or click on the drug name) |
| Suggested lab follow-up | Monthly CBC x 3 months, then every 3months if stable |
| Warning |
5-8% incidence of abacavir hypersensitivity
(see abacavir above) The incidence of abacavir hypersensitivity is slightly higher (8%) with single daily dosing of abacavir in this formulation.
Rare lactic acidosis and hepatic
steatosis. Severe acute exacerbations of chronic hepatitis B may be observed with sudden discontinuation of Epzicom. |
| Contraindication | Previous abacavir hypersensitivity |
|
Suggested administration protocol |
Click HERE to review abacavir administration protocol |
|
Suggested Usage |
Do not use in combination with lamivudine, emtricitabine, Truvada, Combivir, or Trizivir due to identical mechanism of action or duplication of lamivudine dosing. |
|
Complete prescribing information |
Epzicom Prescribing Info |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Fusion Inhibitors |
| enfuvirtide |
Updated 10.25.2005
1. Renal dosing information from: Ian R.
McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal
Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18